Guardant health, inc. (GH)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16
OPERATING ACTIVITIES:
Net loss

-67,851

-84,263

-83,221

-46,139

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

11,411

7,136

5,206

3,693

Amortization of ROU

2,198

0

0

-

Unrealized translation gains (loss) on obligation related to royalty

147

357

-980

0

Re-valuation of contingent consideration

300

0

0

-

Non-cash stock-based compensation

16,954

6,851

3,670

1,971

Non-cash interest expense

0

13

-685

1,024

Loss on debt extinguishment

0

0

-5,100

0

Amortization of premium (discount) on marketable securities

2,310

412

-359

-287

Benefit from income tax differences

-1,597

0

0

-

Changes in operating assets and liabilities:
Accounts receivable, net

7,389

22,903

9,292

2,786

Inventory

6,045

1,849

4,518

351

Prepaid expenses and other current assets

6,185

3,663

-30

610

Other assets

2,852

451

883

-12

Accounts payable

4,341

5,046

1,250

2,145

Accrued compensation

5,571

8,075

2,348

1,374

Accrued expenses

9,213

286

4,657

508

Long-term operating lease liabilities net of ROU

1,039

0

0

-

Deferred rent

0

-1,307

-204

-467

Deferred revenue

-3,861

13,025

1,215

1,695

Other liabilities

76

0

0

-

Net cash used in operating activities

-47,134

-72,185

-72,235

-36,710

INVESTING ACTIVITIES:
Purchases of marketable securities

614,290

287,450

236,835

341,415

Maturity of marketable securities

325,333

154,625

75,402

369,383

Business acquisition, net of cash acquired

7,328

0

0

-

Purchases of property and equipment

18,717

20,203

6,681

1,766

Purchase of intangible assets

2,500

0

0

0

Payment in connection with a license agreement

68

0

2,302

-

Net cash provided by investing activities

-317,570

-153,028

-170,416

26,202

FINANCING ACTIVITIES:
Payments made on royalty obligations

311

0

25,844

379

Payments made on capital lease obligations

128

443

244

-4

Proceeds from issuance of convertible preferred stock, net of issuance costs

0

0

319,536

40,049

Proceeds from issuance of common stock under employee stock purchase plan

6,395

0

0

-

Proceeds from issuance of common stock upon exercise of stock options

11,639

3,111

753

266

Proceeds from issuance of common stock upon the exercise of warrants

0

45

12

0

Repurchase of convertible preferred stock

0

0

5,335

0

Repurchase of common stock

0

172

7,222

100

Proceeds from public offerings of common stock

350,432

254,006

0

-

Proceeds from initial public offering, net of underwriting discounts and commissions

-

-

-

0

Payment of offering costs related to initial public offering and follow-on offering

723

4,386

0

0

Net proceeds from issuance of equity interests in redeemable noncontrolling interest

0

41,000

0

0

Net cash provided by financing activities

367,304

293,161

281,656

39,840

Net effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash

84

0

0

-

Net increase in cash and cash equivalents

2,684

67,948

39,005

29,332

Supplemental Disclosures of Cash Flow Information:
Operating lease liabilities arising from obtaining right-of-use assets

16,714

0

0

-

Cash paid for interest

1,181

1,251

1,339

2,243

Cash paid for income taxes

298

102

26

14

Supplemental Disclosures of Noncash Investing and Financing Activities:
Capitalized license fees financed through future royalty payment

0

0

6,302

0

Increase in purchases of property and equipment included in accounts payable and accrued expenses

3,296

897

591

-

Vesting of common stock exercised early

95

-

-

-

Property and equipment acquired under capital leases

-

-

-

34

Property and equipment acquired under capital leases

0

0

346

468

Conversion of convertible preferred stock to common stock upon initial public offering

0

499,974

0

0

Deferred offering costs included in accounts payable and accrued expenses

0

89

0

0

Common Stock
Payments for Repurchase of Common Stock

-

-

-

194

Vesting of common stock exercised early

95

0

103

-

Stock issued

-

-

-

283

Convertible Preferred Stock
Issuance of Series D convertible preferred stock in exchange for a technology license agreement

0

0

1,060

-

Stock issued

-

-

-

0